Summary
DexCom, Inc. (DXCM) reported strong growth in its 2020 10-K filing, highlighting a 31% increase in total revenue, reaching $1.93 billion. This growth was primarily driven by increased sales volume of its disposable continuous glucose monitoring (CGM) sensors, reflecting continued expansion of its customer base globally. The company also saw an improvement in its gross profit margin to 66% from 63% in the prior year, attributed to higher revenues and manufacturing efficiencies. Operating expenses grew, with a significant portion dedicated to research and development to support next-generation products. The company continues to invest in product innovation, with the development of the Dexcom G7 system emphasizing reduced size, a fully disposable sensor and transmitter design, and faster warm-up times. Dexcom also benefits from strategic partnerships with insulin delivery companies, aiming to integrate its CGM technology into automated insulin delivery systems. The company's commercial strategy focuses on direct sales to healthcare professionals and expanding market access through distribution agreements and direct-to-consumer marketing. Despite challenges like pricing pressure and competition, Dexcom is well-positioned due to its technological leadership and growing market adoption.
Financial Highlights
51 data points| Revenue | $1.93B |
| Cost of Revenue | $646.60M |
| Gross Profit | $1.28B |
| R&D Expenses | $359.90M |
| SG&A Expenses | $618.20M |
| Operating Expenses | $980.60M |
| Operating Income | $299.50M |
| Interest Expense | $17.70M |
| Net Income | $549.70M |
| EPS (Basic) | $1.46 |
| EPS (Diluted) | $1.33 |
| Shares Outstanding (Basic) | 377.50M |
| Shares Outstanding (Diluted) | 420.40M |
Key Highlights
- 1Total revenue grew by 31% to $1.93 billion in 2020, driven by increased sales volume of disposable CGM sensors.
- 2Gross profit increased by 37% to $1.28 billion, with gross profit margin improving to 66% due to revenue growth and manufacturing efficiencies.
- 3Significant investments were made in Research and Development (R&D) (+32%) to support product innovation and future growth.
- 4Selling, General, and Administrative (SG&A) expenses increased by 20%, largely due to higher advertising and marketing costs to drive adoption.
- 5The company is actively developing its next-generation Dexcom G7 system, featuring a 60% size reduction and a fully disposable sensor/transmitter.
- 6Dexcom has established strategic partnerships with major insulin delivery companies to integrate its CGM technology.
- 7The company ended 2020 with $2.71 billion in cash, cash equivalents, and short-term marketable securities, indicating a strong liquidity position.